Cited 0 times in
Appropriate Number of Adjuvant Chemotherapy Cycles for Patients with Stage 2 or 3 Gastric Cancer After Curative Gastrectomy: A Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형일 | - |
dc.date.accessioned | 2021-12-28T17:39:02Z | - |
dc.date.available | 2021-12-28T17:39:02Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187204 | - |
dc.description.abstract | Background: Few studies have presented evidence pertaining to the adequate minimum number of adjuvant chemotherapy (AC) cycles required to achieve an oncologic benefit for gastric cancer. Methods: From January 2012 to December 2013, data from patients who underwent curative radical gastrectomy and consequently received AC for pathologic stage 2 or 3 gastric cancer at 27 institutions in South Korea were analyzed. Results: The study enrolled 925 patients, 661 patients (71.5%) who completed 8 cycles of AC and 264 patients (28.5%) who did not. Compared with the mean disease-free survival (DFS) of the patients who completed 8 AC cycles (69.3 months), the mean DFS of patients who completed 6 AC cycles (72.4 months; p = 0.531) and those who completed 7 AC cycles (63.7 months; p = 0.184) did not differ significantly. However, the mean DFS of the patients who completed 5 AC cycles (48.2 months; p = 0.016) and those who completed 1-4 AC cycles (62.9 months; p = 0.036) was significantly lower than the DFS of those who completed 8 AC cycles. In the multivariate Cox proportional hazards analysis, the mean DFS was significantly affected by advanced stage, large tumor size, positive vascular invasion, and number of completed AC cycles (1-5 cycles: hazard ratio 1.45; 95% confidence interval 1.01-2.08; p = 0.041). Conclusion: The current multicenter observational cohort study showed that the mean DFS for 6 or 7 AC cycles was similar to that for 8 AC cycles as an adjuvant treatment for gastric cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | ANNALS OF SURGICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Gastrectomy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stomach Neoplasms* / drug therapy | - |
dc.subject.MESH | Stomach Neoplasms* / surgery | - |
dc.title | Appropriate Number of Adjuvant Chemotherapy Cycles for Patients with Stage 2 or 3 Gastric Cancer After Curative Gastrectomy: A Multicenter Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Sang-Ho Jeong | - |
dc.contributor.googleauthor | Moon-Won Yoo | - |
dc.contributor.googleauthor | Young-Gil Son | - |
dc.contributor.googleauthor | Sung Jin Oh | - |
dc.contributor.googleauthor | Jong-Han Kim | - |
dc.contributor.googleauthor | Hyoung-Il Kim | - |
dc.contributor.googleauthor | Joong-Min Park | - |
dc.contributor.googleauthor | Hoon Hur | - |
dc.contributor.googleauthor | Ye Seob Jee | - |
dc.contributor.googleauthor | Sun-Hwi Hwang | - |
dc.contributor.googleauthor | Sung-Ho Jin | - |
dc.contributor.googleauthor | Sang Eok Lee | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Kyung Won Seo | - |
dc.contributor.googleauthor | Sungsoo Park | - |
dc.contributor.googleauthor | Chang Min Lee | - |
dc.contributor.googleauthor | Chang Hyun Kim | - |
dc.contributor.googleauthor | In Ho Jeong | - |
dc.contributor.googleauthor | Han Hong Lee | - |
dc.contributor.googleauthor | Sung Il Choi | - |
dc.contributor.googleauthor | Sang-Il Lee | - |
dc.contributor.googleauthor | Chan Young Kim | - |
dc.contributor.googleauthor | Hyundong Chae | - |
dc.contributor.googleauthor | Myoung-Won Son | - |
dc.contributor.googleauthor | Kyung Ho Pak | - |
dc.contributor.googleauthor | Sungsoo Kim | - |
dc.contributor.googleauthor | Moon-Soo Lee | - |
dc.contributor.googleauthor | Jae-Seok Min | - |
dc.identifier.doi | 10.1245/s10434-020-09504-4 | - |
dc.contributor.localId | A01154 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 33423177 | - |
dc.identifier.url | https://link.springer.com/article/10.1245%2Fs10434-020-09504-4 | - |
dc.contributor.alternativeName | Kim, Hyoung Il | - |
dc.contributor.affiliatedAuthor | 김형일 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 4458 | - |
dc.citation.endPage | 4470 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL ONCOLOGY, Vol.28(8) : 4458-4470, 2021-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.